Repros Therapeutics
Inc.^® RPRX today announced that the FDA has agreed to a Type B
meeting scheduled for the last half of May to discuss the Phase 3 development
of Proellex® as a vaginally administered product for the treatment of uterine
fibroids. During the meeting, Repros will discuss the proposed plans for a
Phase 3 study, the FDA's requirements for the size of the safety population
and the adequacy of the already completed preclinical studies to support a
marketing application.
Once the meeting is held, the Company will report the outcome to the financial
community in a timely fashion.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in